Recent Finacing
Recent Raise
SynOx Therapeutics develops emactuzumab, a humanized anti‑CSF‑1R monoclonal antibody to deplete tumor‑associated macrophages, conducting the global TANGENT Phase 3 trial in TGCT and exploring other macrophage‑driven diseases.
